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Patterns of cell cycle checkpoint deregulation associated with
intrinsic molecular subtypes of human breast cancer cells
Jacquelyn J. Bower1,2, Leah D. Vance1, Matthew Psioda3, Stephanie L. Smith-Roe1,6, Dennis A. Simpson1, Joseph G. Ibrahim2,3,4,
Katherine A. Hoadley2,5, Charles M. Perou1,2,4,5 and William K. Kaufmann1,2,4
Genomic instability is a hallmark of breast cancer, contributes to tumor heterogeneity, and influences chemotherapy resistance.
Although Gap 2 and mitotic checkpoints are thought to prevent genomic instability, the role of these checkpoints in breast cancer
is poorly understood. Here, we assess the Gap 2 and mitotic checkpoint functions of 24 breast cancer and immortalized mammary
epithelial cell lines representing four of the six intrinsic molecular subtypes of breast cancer. We found that patterns of cell cycle
checkpoint deregulation were associated with the intrinsic molecular subtype of breast cancer cell lines. Specifically, the luminal B
and basal-like cell lines harbored two molecularly distinct Gap 2/mitosis checkpoint defects (impairment of the decatenation Gap 2
checkpoint and the spindle assembly checkpoint, respectively). All subtypes of breast cancer cell lines examined displayed aberrant
DNA synthesis/Gap 2/mitosis progression and the basal-like and claudin-low cell lines exhibited increased percentages of
chromatid cohesion defects. Furthermore, a decatenation Gap 2 checkpoint gene expression signature identified in the cell line
panel correlated with clinical outcomes in breast cancer patients, suggesting that breast tumors may also harbor defects in
decatenation Gap 2 checkpoint function. Taken together, these data imply that pharmacological targeting of signaling pathways
driving these phenotypes may lead to the development of novel personalized treatment strategies for the latter two subtypes
which currently lack targeted therapeutic options because of their triple negative breast cancer status.
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INTRODUCTION
Cellular division is controlled by a tightly regulated process that
requires accurate separation of sister chromatids upon the
completion of DNA replication in order to produce two genetically
identical daughter cells. The regulatory signals that control cell
division are collectively referred to as the cell cycle, which is
comprised of five distinct phases: quiescence (G0), Gap 1 (G1), DNA
replication/synthesis (S), Gap 2 (G2), and mitosis (M) (Fig. 1).
Transitions between different phases of the cell cycle are induced
via oscillating levels of cyclins and cyclin-dependent kinases
(cdks); each phase of the cell cycle is characterized by the
formation of specific complexes of cyclin/cdk heterodimers.
Intracellular and/or external stimuli can halt progression of the
cell cycle through a complex network of signaling events that
interfere with cyclin/cdk activities controlling cell cycle progres-
sion. This pause in cell cycle progression is often referred to as a
“checkpoint” and allows the cell time to repair damaged DNA or
acquire sufficient levels of growth factors before transitioning to
the next phase; if the DNA damage is too severe to repair, the cell
may activate apoptotic signaling cascades to prevent the
transmission of damaged DNA to its daughter cells. Thus, cell
cycle checkpoints ensure ordered progression of the cell cycle, are
critical for maintaining genomic stability, act as barriers to
carcinogenesis, and are often deregulated in tumors.1–3
At least four cell cycle checkpoints may be deregulated in
cancer cells: the restriction point (G0/G1), the G1 checkpoint, the G2
checkpoint, and the mitosis-associated spindle assembly check-
point (SAC). The G0/G1 restriction point is the point in G1 at which
the withdrawal of growth factors no longer induces reversion to a
quiescent state; thus, it controls the cell’s commitment to
division.4 The restriction checkpoint is largely controlled by the
Rb/E2F signaling pathway: release of E2F transcription factors from
Rb allows E2F to transcriptionally activate genes that promote the
initiation of DNA replication and S phase entry. Both over-
expression of upstream regulators of Rb (such as Cyclin D1/cdk4/
6) or inactivating mutations in the RB1 gene can degrade this
checkpoint and lead to early activation of DNA replication.5, 6
The G1 DNA damage checkpoint delays the initiation of DNA
replication in the presence of DNA damage and is largely
controlled by the p53/p21/Mdm2 pathway.7, 8 Loss of this
checkpoint can often occur via TP53 mutations or inactivation of
wild-type p53 by viral proteins and lead to error-prone DNA
synthesis due to the diminished amount of time allotted for DNA
repair.9, 10
Two types of G2 checkpoint responses have been previously
identified: the DNA damage G2 checkpoint and the decatenation
G2 checkpoint.
11–13 The DNA damage G2 checkpoint delays the
initiation of mitosis upon DNA damage by sequestering inactive
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cyclin B1/cdk1 in the cytoplasm, thus preventing entry into
mitosis.14, 15 The decatenation G2 checkpoint is molecularly
distinct from the DNA damage G2 checkpoint in that it is activated
in response to catalytic inhibition of topoisomerase IIα (topo IIα)
without overt DNA damage.12, 16, 17 Major players in both the DNA
damage and decatenation G2 checkpoint include the ATM/Chk2/
p53 pathway and attenuation of either G2 checkpoint leads to
chromosomal instability.18 Finally, the SAC acts in mitosis to delay
the onset of anaphase until all chromosomes exhibit bipolar
attachment to the mitotic spindle.2, 19, 20 Major effectors of SAC
function include APC/C, BubR1, and Mad2, and impaired SAC
signaling often leads to the formation of multipolar spindles and/
or the unequal partitioning of sister chromatids into daughter
cells.21 Defects in all of these cell cycle checkpoints have been
shown to play an integral role in tumor initiation and/or
progression and affect the sensitivity of tumors to both cytotoxic
and endocrine drugs.22–24
The role of the restriction and G1 checkpoints in breast cancer
signaling, genome maintenance, and chemosensitivity has been
previously characterized;24, 25 however, the relationship between
G2 or SAC checkpoint function, genomic instability, and chemore-
sistance is poorly understood. Six intrinsic molecular subtypes of
breast tumors have been proposed,26, 27 and several studies imply
that these subtypes contain similar molecular defects that
contribute to disease progression and variability in chemother-
apeutic response,28-30 which may confer synthetic lethality to
subsets of cancer cells.31, 32 Although these studies imply that
genomic instability plays a role in these processes, the nature of
the specific molecular defects contributing to breast cancer
outcomes remains elusive. To explore the underlying mechanisms
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Fig. 1 Diagram of cell cycle regulation. Phases of the cell cycle are shown inside the blue circle in the center of the figure (G0, G1, S, G2, and
mitosis which consists of several sub-phases: prophase (Pro), metaphase (Met), anaphase (Ana), and telophase (Tel)). The G0 Restriction Point is
designated with a yellow dual headed arrow to illustrate the reversible nature of cell cycle entry and quiescence. As cells progress through the
cycle, exogenous perturbations can activate checkpoints that arrest cells during phase transitions (checkpoints are designated by yellow
lightning bolts). Several measures of cellular proliferation are shown in green and span the cell cycle phases in which these markers are present.
Drugs that inhibit cell cycle progression are shown in orange with their targets and mechanisms of action designated in subsequent
parentheses. Components of major regulatory pathways triggering each checkpoint are listed in dark blue font near the checkpoint in which
they play a role. Precise control over the regulation of the cell cycle is a requirement for ensuring accurate DNA replication and cell division
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functions were assessed in a panel of 24 cell lines using a flow
cytometry-based mitotic entry rate (MER) assay that allows for
discrimination among three molecularly distinct G2/M check-
points: the DNA damage G2 checkpoint, the decatenation G2
checkpoint, and the SAC. The panel is comprised of cell lines
representing four of the six intrinsic molecular subtypes of breast
tumors: six luminal B (LumB), four basal-like (BL), six claudin-low
(CL), and four Her2-enriched (Her2E) cell lines. Luminal A and
normal-like breast cancer cell lines are unavailable, and four
immortalized non-tumorigenic human mammary epithelial cell
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lines (HMECs) were employed as positive controls. These cell lines
recapitulate the gene expression profiles, abnormal genomic
features, and phenotypes of in vivo breast tumors,33-35 and exhibit
subtype-specific responses to several chemotherapeutic agents.32
Because no comprehensive functional analysis of G2/M check-
points has been described for breast cancer cell lines to date and
existing reports almost exclusively utilize three breast cancer cell
lines (MCF7, HCC1937, and MDA-MB-231) to investigate the
accumulation of cells in G2/M (but not checkpoint function), the
data generated from this study provides a valuable resource for
delineating the role of G2/M checkpoints in breast cancer cells.
Furthermore, the findings of this study indicate that deregulation
of G2 and M checkpoint functions, aberrant cell cycle regulation
patterns, and chromatid cohesion defects coincide with breast
cancer intrinsic molecular subtypes and that a gene signature for
decatenation G2 checkpoint function identified in the cell line
panel correlates with clinical outcomes in breast cancer patients.
These data collectively suggest that pharmacological targeting of
pathways driving these genomic instability phenotypes may lead
to the development of new personalized treatment strategies for
breast cancer subtypes that currently lack targeted therapies.
RESULTS
The decatenation G2 checkpoint is impaired in LumB breast cancer
cell lines
To assess G2/M checkpoint function, a MER assay utilizing two
topo II inhibitors exhibiting distinct mechanisms of action was
employed to monitor the G2-M transition rate. Cells were
incubated with colcemid (to prevent mitotic exit) for 2–6 h in
the presence or absence of the topo II catalytic inhibitor ICRF-193
(which does not overtly damage DNA) to measure decatenation
G2 checkpoint function or the topo II poison etoposide (which
induces DNA damage) to measure DNA damage G2 checkpoint
function at concentrations that arrest 98–100% of normal human
diploid fibroblasts (NHF1-hTERTs) and immortalized lymphoblasts
in G2.
36 The use of colcemid in the MER assay blocks cells from
exiting mitosis, allowing for a strict examination of the G2 to M
transition, thus minimizing any confounding effects related to the
rate of mitotic exit. The MER was calculated from the linear portion
of the resulting line (2–6 h time points) and is expressed as the
percentage of cells entering mitosis per hour.36
MER examples are shown for the HMEC cell line R-HMEC-E in the
left panel of Fig 2a. These cells accumulated in mitosis when
incubated in colcemid (and the vehicle control dimethyl sulfoxide
(DMSO), closed squares) reflecting their transition from G2 to M;
however, in the presence of the catalytic inhibitor ICRF-193 (open
circles), mitotic accumulation of R-HMEC-E cells was severely
inhibited suggesting that the majority of these cells activate a
decatenation G2 checkpoint response. In the presence of the topo
II poison etoposide, the mitotic accumulation of R-HMEC-E cells
was also severely inhibited (closed triangles), indicating that this
cell line exhibits an effective DNA damage G2 checkpoint.
Conversely, the LumB breast cancer cell line MDA-MB-453
continued to accumulate in mitosis in the presence of ICRF-193,
but not etoposide (Fig. 2a, right panel), suggesting that a majority
of these cells evaded the decatenation G2 checkpoint but arrested
in G2 upon DNA damage.
All 24 cell lines were subjected to the MER-based G2 checkpoint
assay and the averages of three independent experiments for
each cell line (grouped according to molecular subtype) are
shown in Fig. 2b (individual cell line averages ± SEM are provided
in Table S1). As expected, all four positive control HMEC cell lines
displayed severe MER inhibition in response to ICRF-193 suggest-
ing that this class exhibits an effective decatenation G2
checkpoint. In contrast, checkpoint functions of the breast cancer
cell lines were highly variable (Fig. 2b). Upon grouping the cell
lines by intrinsic molecular subtype, the LumB and BL cell lines
appeared to exhibit attenuated decatenation G2 checkpoint
function, whereas the HER2E and CL subtypes displayed
checkpoint function similar to the HMECs. A set of statistical
linear mixed models (LMMs) was employed to compare G2
checkpoint functions among the different subtypes (see Supple-
mentary Information, (SI)). These analyses established that the
LumB class (but not the BL class) of breast cancer cell lines
exhibited defects in decatenation G2 checkpoint function (**p <
0.05, FDR < 0.05). Although the distribution of % inhibition of MER
in the BL cell lines initially appeared similar to that of the LumB
group, closer inspection of the MER data revealed that the BL
group exhibited very low MERs in the absence of a topo II catalytic
inhibitor, indicating that this group was not responding to
colcemid treatment; thus, the percent inhibition of MER appears
artificially low in the BL group.
Complementary experiments were performed to assess
whether breast cancer cell lines were capable of activating the
DNA damage G2 checkpoint using a concentration of the topo II
poison etoposide equivalent to that of the catalytic inhibitor ICRF-
193 (4 µM). All four HMEC cell lines displayed an effective DNA
damage G2 checkpoint in response to etoposide (Fig. 2c). The
majority of the breast cancer cell lines also exhibited large MER
inhibition in the presence of etoposide and no significant
differences were observed for any of the breast cancer cell line
classes; thus, these breast cancer cell lines were capable of
activating the DNA damage G2 checkpoint at levels comparable to
those of HMECs, with the exception of the DU4475 LumB cell line
(Table S1).
To confirm that ICRF-193 was able to inhibit topo II activity in
the LumB cell lines, cytogenetic preparations were examined in
the presence or absence of ICRF-193 and representative
metaphases of two LumB cell lines are shown in Fig. 2d. In the
presence of DMSO, the majority of the LumB metaphases
exhibited individualized condensed chromosomes. However,
Fig. 2 The decatenation G2 checkpoint response is impaired in luminal B (LumB) breast cancer cell lines. A panel of non-tumorigenic
immortalized mammary epithelial cell lines (HMEC) and breast cancer cell lines were assessed for G2 and M checkpoint functions using a
mitotic entry rate (MER) assay to monitor the rate of the G2/M transition in the presence of the topo II catalytic inhibitor ICRF-193
(decatenation G2 checkpoint) or the DNA-damaging topo II poison etoposide (DNA damage G2 checkpoint). a Example MERs of an HMEC (R-
HMEC-E) cell line with effective decatenation and DNA damage G2 checkpoints and a LumB (MDA-MB-453) cell line with a defective
decatenation G2 checkpoint. b and c The average percent inhibition of the MER of each cell line grouped according to intrinsic molecular
subtype. Each point on the graph represents the average of 3 independent experiments for an individual cell line, and the bold lines represent
the class average. d Example metaphases of LumB cell lines in the presence of DMSO exhibiting individualized chromosomes. Severely under-
condensed and/or entangled chromosomes were observed in >88% of LumB cells upon treatment with 4 µM ICRF-193, suggesting that ICRF-
193 is capable of inhibiting topoisomerase II in LumB cell lines. Percentages of entangled/under-condensed chromosomes are shown in the
lower right hand corner of each ICRF-193 treated example. e HMECs activate p-Ser15 p53 after ICRF-193 or etoposide treatment (top panel).
The HME-CC etoposide sample displayed aberrant mobility of ATM and reduced expression of p53 which could not be reproduced; therefore,
this sample was omitted from the analysis. LumB cell lines exhibit reduced levels of p-Ser15 p53 in response to ICRF-193 (lower panel).
Quantification of p53 activation is shown in the right panel. Data are representative of two independent experiments. *p-value< 0.05, **p-
value that remains significant when controlling for FDR (5%), BL: basal-like, CL: claudin-low, Her2E: Her2-enriched
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upon inhibition of topo II with ICRF-193, >88% of all LumB mitotic
cells displayed chromosomes that were under-condensed and/or
entangled (data not shown). Thus, the observed defect in
decatenation G2 checkpoint function was unlikely to be the result
of a failure of ICRF-193 to inhibit topo II catalytic activity in the
LumB class, supporting the conclusion that the defect is due to
dysfunctional checkpoint activation and not an inability of the
LumB class to respond to ICRF-193 treatment.
Previous studies demonstrate that p53 is activated in response
to ICRF-193, and cell lines with defective decatenation G2
checkpoint function exhibit attenuated activation of p53.36, 37
Therefore, the LumB and HMEC classes were examined to
determine whether cell lines lacking a decatenation G2 checkpoint
exhibit attenuated p53 phosphorylation. To facilitate comparisons
across different blots and account for exposure differences, the
same NHF1-hTERT sample was loaded onto each gel and the
increment of activation of p-Ser15 p53 for each cell line was
normalized to that of the NHF1-hTERT internal control. As shown
in the upper panel of Fig. 2e, all four HMEC cell lines responded to
ICRF-193 with induction of total p53 and p-Ser15 p53. Larger
increases in p-Ser15-p53 were observed upon etoposide treat-
ment in the majority of HMEC cell lines, signifying that activation
of p53 signaling by ICRF-193 in HMECs is similar to that observed
in other non-tumorigenic cell lines.36 In contrast, the LumB cell
lines exhibited attenuated induction of p-Ser15 p53 in response to
ICRF-193 (Fig. 2e, bottom panel). At least two of these cell lines
(HCC1428 and MDA-MB-453) appeared to express low or
undetectable levels of p53 despite harboring wildtype TP53
genes.38 Only the MDA-MB-415 cell line exhibited a mutant form
(Y236C) and high basal levels of p53, suggesting that p53
activation was attenuated by a mechanism other than mutation
in most of the LumB lines. The increment of p-Ser15 p53 upon
etoposide treatment for the LumB class was not statistically
different from the HMEC class (Fig. S1B), suggesting that
attenuated signaling was not due to the loss of an inherent
ability to phosphorylate Ser15 of p53, but rather was less
responsive to topo II catalytic inhibition.
Activation of p-Ser 1981 of ATM and p-Thr 68 of Chk2 can
contribute to p-Ser15 activation of p53 and have also been
observed upon ICRF-193 exposure;36 however, no significant
differences in ATM or Chk2 activation were observed in the LumB
class when compared to the HMEC class, likely due to high levels of
variation among cell lines (Fig. S1A–B). Western blots of all cell lines
comprising the remaining intrinsic subtypes are shown in Fig. S1C-
G. None of the intrinsic subtypes exhibited a statistically significant
decrease in ATM or Chk2 when compared to the HMEC class upon
either ICRF-193 or etoposide exposure (Fig. S1B); however, the
Her2E class also exhibited attenuated activation of p53 in response
to ICRF-193. Due to the short exposure time (3 h), this may be a
result of the slower growth rate of the Her2E lines as described
further below. Taken together, these results indicate that the LumB
class harbors a defective decatenation G2 checkpoint.
Breast cancer cell lines exhibit altered S/G2/M cell cycle
progression
During the initial G2/M checkpoint screen, several cell lines
exhibited a low MER (Table S1). Because interpretation of
checkpoint function can be confounded by differential growth
rates, the cell line panel was assessed for differential patterns of
cell proliferation and/or deregulated cell cycle progression kinetics
to account for inherent differences in cell cycle phase length that
might interfere with interpretation of the G2/M checkpoint
functionality experiments and to ensure that the LumB defect in
decatenation G2 checkpoint function was not attributable to
inherent differences in MER. Such confounding effects have been
previously reported and are often due to the dependency of some
checkpoint assays on singular markers of cell proliferation.36
Three measures of cell proliferation were compared via
flow cytometry including the S phase fraction as determined
by EdU incorporation (S), the mitotic index (MI) as measured by
MPM2+/4N DNA content, and the MER. The number of population
doublings (PDLs) occurring during continuous culture was also
determined by counting the total number of cells during each
passage and calculating the doubling time of each cell line (PDL/
week). In Fig. 3 a–d, the individual averages for each cell line are
depicted and grouped by molecular subtype. (Averages for each
cell line ± SEM are provided in Table S2).
In Fig. 3a, the S phase fractions of the Her2E and LumB subtypes
appeared lower than the other classes. LMM analysis supported
the observation of a decrease in S for the Her2E class, but the
decrease in LumB lines was not statistically significant suggesting
that the HMEC, BL, CL, and LumB classes exhibit comparable
percentages of cells undergoing DNA replication. In Fig. 3b, the BL
cell lines exhibited an increased MI compared to the HMECs, and
LMM analysis reinforced this observation suggesting that the
HMEC, CL, LumB, and Her2E classes exhibit similar MIs. In Fig. 3c,
the MER of the BL, CL, and Her2E classes were lower than the
HMEC class; these observations were corroborated by LMM
analysis and suggest that only the HMEC and LumB classes
exhibited similar MERs. In Fig. 3d, PDL measurements suggested
that the LumB and Her2E subtypes have lower PDLs, and LMM
analysis validated that both classes exhibited significantly lower
PDLs when compared to the HMEC class. The LumB class was
comparable to the HMEC class by every other measure of cell
proliferation, indicating that a MER comparison of the HMEC and
LumB classes was an appropriate measure of both decatenation
and DNA damage G2 checkpoint function in LumB cell lines. (**p <
0.05, FDR < 0.05)
Because the completion of DNA replication is coupled to the
onset of mitosis, concomitant increases in multiple measures of
cell proliferation (Fig. 3a–c) are expected to occur in cells that
maintain strict regulatory control over S/G2/M cell cycle progres-
sion to preserve a diploid genome.39, 40 Conversely, this relation-
ship would be disrupted if cell cycle phase transitions were
deregulated. Thus, two adjacent markers of cell cycle phase were
assessed for the presence of a correlative relationship,41 and an
absence of correlation between those markers would imply that
the transition between those two cell cycle phases was delayed
and/or aberrantly regulated.
The HMEC and LumB classes exhibited a highly correlative
relationship between S phase fraction and MI (p < 0.0001 and
0.0041, respectively, Table 1), suggesting that the cell cycle
transitions among S/G2/M phases follows an ordered progression.
However, the BL, CL, and Her2E classes exhibited no correlative
relationship between S phase fraction and MI suggesting that cell
cycle progression is delayed or aberrantly regulated at some point
between the initiation of DNA replication and mitotic exit. To
further refine the deregulated point(s) in the cell cycle, S phase
fraction was compared to the MER measurement to determine if S
or G2 progression was delayed. Only the HMEC class (p = 0.0006)
exhibited a correlation between the S and MER; all of the breast
cancer cell line classes displayed decoupling of the S phase
fraction and MER suggesting that these classes may spend longer
periods of time in the S or G2 phases, or exhibit aberrant cell cycle
control during S/G2. Finally, the HMEC, LumB, and CL classes all
exhibited a correlative relationship between the time-dependent
MER and MI (p = 0.012, p < 0.0001, and p = 0.0051, respectively)
suggesting that these classes maintain ordered mitotic progres-
sion. In contrast, the BL and Her2E classes showed no significant
correlation between MER and MI, indicating that these classes may
not respond to the microtubule polymerization inhibitor colcemid
and/or exhibit difficulty completing mitosis. (*p < 0.05, **p < 0.05,
FDR < 0.05)
Only the non-tumorigenic HMEC class exhibited a correlative
relationship among all three proliferation markers, suggesting that
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regulation of the cell cycle in HMECs is linked, occurs in an ordered
progression, and illustrates the tightly controlled regulation of
S/G2/M progression kinetics in non-tumorigenic cells. In contrast,
breast cancer cell lines exhibited deregulation of one or more
distinct cell cycle phases suggesting that S/G2/M progression was
delayed or altered. The BL and Her2E classes displayed no
correlative relationships, suggesting that multiple defects in cell
cycle regulation were present. Because the data in Fig. 3a–d
demonstrate that the Her2E class also exhibited lower prolifera-
tion rates in culture when compared to the HMECs, we are
reluctant to make conclusions regarding cell cycle checkpoint
function in cell lines of the Her2E class without additional data. In
summary, these data suggest that breast cancer subtypes are
associated with altered regulation of S/G2/M progression, and that
the BL and CL classes may exhibit S/G2/M progression defects that
evaded detection by the MER assay.
CL and BL breast cancer cell lines harbor chromatid cohesion
defects; the SAC is impaired in BL breast cancer cell lines
To determine whether the BL and CL classes exhibited S/G2/M
checkpoint defects that were not identified by the MER screen,
metaphases were analyzed to evaluate gross chromosomal
structure aberrations which are often indicative of checkpoint
defects. All metaphases were scored in a blind manner, and
example spreads are shown in Fig. 4a for an HMEC, BL, and CL cell
line. Overall, metaphases of the LumB, and Her2E classes exhibited
similar probabilities of harboring a cohesion defect when
compared to the HMEC class (Table S3A, p = 0.1674 and
p = 0.4743, respectively). In contrast, the CL and BL classes
appeared to exhibit an increased probability of harboring
cohesion defects that ranged from mild to severe (Fig. 4a).
****
** ** ** ****
A B
C D
Fig. 3 S/G2/M progression is aberrantly regulated in breast cancer cell lines of all classes. The average percentage of cells in S phase (a) or
mitosis (b) and the MER (c) is shown for each cell line and grouped according to intrinsic molecular subtype. Each point represents the
average of at least three independent experiments for an individual cell line, and the bold lines represent the class average. The Her2E class
exhibited a lower S phase fraction, the BL class demonstrated a higher MI, and the BL, CL, and Her2E classes displayed lower MERs when
compared to the HMEC class. d The population doubling level (PDL) over at least 11 weeks in cell culture was determined for each cell line,
and the bold lines represent the class averages; both the LumB and Her2E classes exhibited low PDLs. *p-value< 0.05, **p-value that remains
significant when controlling for false discovery rate (5%)
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Due to the variable range of cohesion defect severity,
metaphases were examined via a high sensitivity fluorescence
in situ hybridization (FISH) assay utilizing a probe targeting the
centromere of chromosome 9 (CEP9) to confirm the presence of
cohesion defects and evaluate severity in the BL and CL classes. In
diploid metaphase cells with properly cohered sister chromatids,
the centromeres of the sister chromatids are so close together that
they appear to be a single CEP9 locus upon FISH staining.
However, in cells exhibiting cohesion defects, the centromeric
regions of the sister chromatids are separated and exhibit a
doublet pattern containing two visually distinct CEP9 loci. Degrees
of cohesion defects were defined as mild, moderate, or severe,42
and examples are shown in Fig. 4b with white arrows indicating
each type of cohesion defect. The BL and CL classes both
exhibited increases in the total percentage of cells with cohesion
defects, suggesting that these classes may experience difficulty
completing DNA replication and/or partitioning sister chromatids
equally into daughter cells. Furthermore, distributions of cohesion
defect severity in both classes also differed when compared to the
HMECs, suggesting that an increased number of moderate/severe
cohesion defects were found in these classes (Fig. 4b, lower panel).
In addition, both the BL and CL classes exhibited significantly
higher percentages of cells with aneuploidy when compared to
HMECs (>4 CEP9 foci per metaphase), suggesting that cohesion
defects may lead to inappropriate segregation of duplicate
chromosomes during cytokinesis and confirming the presence
of genomic instability in these classes (Fig. S2 and Table S3B).
Because the MERs of the CL and BL classes were low compared
to the HMEC class (Fig. 3c), the presence of cohesion defects
(Fig. 4a, b) have been previously shown to activate the SAC,43 and
severe aneuploidy was observed in both classes (Table S5B,
Fig. S2), it was possible that the BL and CL classes harbored SAC
defects. Thus, the number of mitotic cells that accumulated over a
24 h period in the presence/absence of colcemid were measured
by flow cytometry.19, 44 This assay allows us to distinguish
between cell lines that exhibit a low MER due to slow movement
through S and/or G2 phase (appreciable levels of mitotic
accumulation in the presence of colcemid appear over 24 h) and
cell lines that lack a functional SAC (no mitotic accumulation due
to an inability to arrest in colcemid). Example flow cytometry
profiles for MCF10As (HMEC) and MDA-MB-468s (BL) are shown in
the left panel of Fig. 4c. Addition of 100 ng/mL colcemid
dramatically increased the number of mitotic cells in the MCF10As,
whereas the number of mitotic cells decreased in the MDA-MB-
468s (Fig. 4c, middle panels). The average increase in mitotic index
for each cell line grouped by intrinsic molecular subtype is shown
for three independent experiments (right panel, Fig. 4c). Individual
cell line averages are provided in Table S4. Both the BL and the
Her2E classes appeared to exhibit a defective SAC, and LMM
analysis confirmed that SAC function was reduced in the BL class.
Although one BL cell line (SUM149) exhibited some mitotic
accumulation in the presence of colcemid, this result is likely due
to the presence of a subpopulation of CL cells found in this cell
line.34 Taken together, these data suggest that the combined
cohesion defects and aberrant SAC function identified in the BL
class may contribute to the high levels of genomic instability
observed in BL breast cancers. The presence of an effective SAC in
the CL class suggests that cohesion defects in these cell lines are
capable of activating the SAC and that the severe aneuploidy
observed is likely due to an alternative mechanism of genomic
instability. (*p < 0.05, **p < 0.05, FDR < 0.05)
A decatenation G2 checkpoint gene expression signature
correlates with clinical outcomes of breast cancer patients
To determine whether the checkpoint defects identified in the cell
line panel were associated with clinical outcomes, a gene
expression signature of decatenation G2 checkpoint function
was identified from the cell line panel using quantitative trait
analysis (QTA) (Table S5). This signature was applied to the
METABRIC clinical data set, which contains approximately 2000
breast tumor samples that include clinical annotations, intrinsic
molecular subtyping information, and gene expression data.45 In a
univariate analysis, the decatenation G2 checkpoint signature was
significantly associated with better overall survival in all breast
tumors (HR: 0.7391, CI: 0.5759–0.9486, log rank p = 0.0176, Fig. 5a).
In a multivariate analysis including the intrinsic molecular
subtypes, the checkpoint signature was not significantly asso-
ciated with overall survival (HR: 0.76843, CI: 0.5769–1.023, log rank
p = 0.071673), but was close to significant.
The decatenation G2 checkpoint signature was also predictive
of OS outcomes in LumA patients (HR: 0.6039, CI: 0.4559–0.7998, p
= 0.01741, Fig. 5b), suggesting that impaired decatenation G2
checkpoint function may contribute to poor outcomes in the
LumA subtype. The median decatenation G2 checkpoint signature
for all breast tumors varied among the subtypes (p = 1.73e–133,
Fig. 5c) with the LumB subtype expressing the lowest median
checkpoint signature; this observation was independently verified
using the UNC337 data set (p = 8.46e–20, Table S6).27 Although
the decatenation G2 checkpoint signature was not significantly
associated with outcomes within the LumB subtype (p = 0.597,
Table S6), this may be due to the inherently low median
decatenation G2 checkpoint signature within this subtype. For
example, if the majority of LumB tumors are defective for
decatenation G2 checkpoint function, there may not be enough
variation of the signature within the LumB subtype to predict
outcomes. Taken together, these data imply that the decatenation
G2 checkpoint may be a clinically relevant target for the treatment
of LumA and/or LumB breast cancer patients.
DISCUSSION
Although several studies have focused on cell cycle control of
human breast cancers and breast cancer cell lines at the G1/S
transition, only a few have examined G2/M checkpoints in multiple
cell lines.46, 47 However, these studies didn’t address DNA damage
G2 or decatenation G2 checkpoint function, nor did they consider
the intrinsic molecular subtype of the cell lines. Therefore, the
well-characterized panel of breast cancer and HMEC cell lines
described in this work provides a valuable resource summarizing
cell cycle checkpoint deregulation and genomic instability patterns
observed in a breast cancer cell line model system (Table 2).
Table 1. Predictive relationships between cell cycle growth phases
based on cell proliferation markers
Cell line
class
S:MI S:MER MER:MI Significant
predictive
relationships
HMEC <0.0001** 0.006** 0.0120* S→MER, MER→MI,
and S→MI
BL 0.5996 0.5954 0.1659 N/A
LumB 0.0041* 0.4769 <0.0001** MER→MI, S→MI
CL 0.4827 0.3758 0.0051* MER→MI
Her2E 0.0706 0.3090 0.1309 N/A
Breast cancer cell lines exhibit impaired cell cycle regulation and S/G2/M
progression kinetics. Associations between the S:MI, S:MER, and MI:MER
growth parameters were assessed for each class. Significant correlations
are shown in the right column. Only the HMEC class showed significant
associations among all three parameters; all breast cancer cell line classes
exhibited aberrant progression kinetics for at least one cell cycle phase
transition. *p-value< 0.05, **p-value that remains significant when
controlling for false discovery rate (5%)
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Fig. 4 The BL and CL cell line classes exhibit chromatid cohesion defects; the BL class also harbors a defective SAC. a Examples of cohesion
defects observed in metaphase. The percentages of cells containing cohesion defects is shown for each cell line in the lower right corner of
the cohesion defect picture. A “railroad” (RR) chromosome lacking a centromeric constriction point is designated with a black arrow in the
SUM149 cell line to exemplify a mild cohesion defect. A severe cohesion defect is exemplified by the complete discohesion of the MDA-MB-
436 metaphase. b Representative examples of the severity of cohesion defects observed during FISH analysis (upper panels). White arrows
designate the centromere used for cohesion defect classification. Quantification of cohesion defects (lower panel) demonstrate that both the
BL and CL classes exhibited variation in the distribution of chromatid cohesion defect severity when compared to the HMECs. Results shown
were obtained from at least four different biological replicates for each subtype. c Flow cytometry examples reflecting SAC function in an
HMEC line (MCF10A) and a BL breast cancer line (MDA-MB-468). Individual cell line averages obtained from at least three independent
experiments are shown with bold lines representing the class average; the BL class exhibited a decrease in SAC function (right panel). *p-value
< 0.05, **p-value that remains significant when controlling for false discovery rate (5%)
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The results of this study indicate that intrinsic subtypes are
associated with unique combinations of genomic instability
patterns including aberrant cell cycle progression kinetics,
chromosomal aberrations, and defective G2 or M checkpoints.
The initial G2/M checkpoint screen revealed that the LumB class
exhibited a defect in decatenation G2 checkpoint function while
remaining capable of activating the DNA damage G2 checkpoint
(Fig. 2b, 2c), and the results in Fig. 3c and Table 1 support the use
of the MER assay as an appropriate measure of G2 checkpoint
function in LumB cell lines. The defect in decatenation G2
checkpoint function was observed in concordance with an
attenuation of p-Ser15-p53 upon catalytic topo II inhibition with
ICRF-193 (Fig. 2e). Although the rate of TP53 mutation in primary
LumB breast tumors is approximately 30%,48 most of the LumB
cell lines examined harbored wild-type TP53 (Table S7), but failed
to significantly activate p53 upon ICRF-193 treatment while
retaining at least partial p53 activation in response to etoposide.
These results suggest that although both drugs share the same
target (topo II), they elicit distinct signaling responses in the LumB
class and provide further support for the G2 checkpoint results
(Fig. 1b).
Decatenation G2 checkpoint defects have also been observed in
lung, bladder, melanoma, and colon cancer cell lines.37, 49–51 Two
reports have also demonstrated that decatenation G2 checkpoint-
defective melanoma and colon cancer cell lines are hypersensitive
to PI3-kinase inhibitors and topo II catalytic inhibitors, respec-
tively.51, 52 Because the decatenation G2 checkpoint response is
molecularly distinct from the DNA damage G2 checkpoint and the
SAC,1, 16, 17 and the gene expression signature of decatenation G2
checkpoint function identified in this study is associated with OS
outcomes in breast cancer patients (Fig. 5, Table S6), it may be
feasible to induce synthetic lethality in tumors exhibiting defects
in decatenation G2 checkpoint function with pharmacological
agents that catalytically inhibit topo II activity, providing an
alternative strategy for targeted drug design to treat poor
prognosis LumB breast cancers and a subset of LumA breast
cancers. Potential agents that may enhance the cytotoxicity of
decatenation G2 checkpoint-defective tumor cells include dexra-
zoxane, an FDA-approved topo II catalytic inhibitor currently used
to prevent anthracycline-induced cardiotoxicity, and PI3 kinase
inhibitors that are currently in clinical trials for multiple solid
tumors.
The low MERs of the BL and CL classes (Table S2 and Fig. 3c) and
insignificant correlations between S:MER and MER:MI (Table 1)
prompted the examination of metaphases to assess underlying
mechanisms that might lead to altered S/G2/M progression. Both
classes displayed increased levels of cohesion defects and
aneuploidy (Fig. 4 and Fig. S2); however, only the BL class failed
to activate a SAC response (Fig. 4c). Although a recent report has
suggested that two SAC markers are activated in response to
Docetaxel in BL cell lines, functional checkpoint assays were not
performed suggesting that aberrant activation of those SAC
markers may not be the underlying cause of SAC dysfunction.53
The significance of these results is further underscored by
studies demonstrating that an effective SAC is required for both
paclitaxel and anthracyclines to exert cytotoxic effects, and that in
the absence of an effective SAC these drugs induce ploidy
increases.22, 23 These data suggest that the high incidence of
cohesion defects coupled with a defective SAC may promote
genomic instability, contribute to high relapse rates, and represent
a potential synthetic lethal target for BL breast tumors.22, 23, 43, 54
Similar to the BL class, the CL cell lines exhibited a lower MER
(Fig. 2c) and an increase in the presence of cohesion defects;
however, the CL class maintained an intact SAC (Fig. 3a, b)
suggesting that an alternative mechanism of genomic instability
may be present in this class of cell lines. Curiously, the CL class
exhibited similar PDL levels, S, MI, and SAC function in comparison
to HMECs (Fig. 3a–d, 4d); however, the lower MERs of this class
suggest that these cells may transit through S or G2 at a slower
rate. Although it is presently unclear what effects sister chromatid
cohesion defects may have in the CL subtype, similar mild
cohesion defects are associated with genomic instability and the
inactivation of MRE-11, SMC1, and CDC4/FBXW7 in colorectal
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Fig. 5 A decatenation G2 checkpoint gene expression signature
correlates with clinical outcomes of breast cancer patients. a gene
expression signature that positively correlated with decatenation G2
checkpoint function in the breast cancer cell line panel was
identified and its relationship with clinical outcomes in the
METABRIC study was assessed using a Cox proportional hazards
model. A high expression of the decatenation G2 checkpoint
signature was associated with better overall survival (OS) in all
breast tumors (log rank p= 0.0176). b For the LumA subtype of
breast tumors, high expression of the decatenation G2 checkpoint
was associated with better OS outcomes (Log Rank p= 0.01741). c
Median decatenation G2 checkpoint signature varies with intrinsic
molecular subtype; LumA and LumB breast tumors exhibited the
lowest median expression of the decatenation G2 checkpoint
signature. HR: hazard ratio, OS: overall survival, CI: confidence
intervals
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cancers42 and future studies will attempt to further characterize S/
G2/M cell cycle progression defects in the CL subtype.
Components of the cell cycle regulatory machinery and
checkpoint function affect the response to chemotherapy in
breast cancer cells.24 Due to the increasing utilization of breast
cancer intrinsic molecular subtypes in clinical settings for
prognostic purposes and chemotherapeutic treatment guidance,
the identification of subtype-associated genomic instability trends
in a standardized panel of in vitro cell lines may contribute to the
development of diagnostic assays, novel targeted drug therapies,
and new personalized chemotherapy regimens. For example,
drugs that target aberrant cell cycle control at the G0/G1 restriction
point such as the cdk4/6 inhibitor Palbociclib® have recently been
approved by the FDA to treat hormone therapy-resistant ER+
tumors and are currently being exploited in the clinic to induce
synthetic lethality in cancers exhibiting deregulation of the RB/
cyclin D1 pathway.25 Although we attempted to identify subtype-
specific genetic mutations in the breast cancer cell line panel that
might contribute to the observed genomic instability patterns and
identify potential synthetic lethal targets, the resulting data
analysis failed to reveal subtype-specific mutations (Fig. S3 and
Table S8), similar to published results for primary breast tumors.48
The significance of the subtype-associated genomic instability
mechanisms outlined herein is further enhanced by the observa-
tion that intrinsic molecular subtypes can often indicate an
intermediate phenotype; thus, the use of functional G2/M
checkpoint assays or other measures of genomic instability to
complement current clinical determinants of chemotherapeutic
response may help relieve some of the ambiguity surrounding
these “borderline” tumors. We speculate that hetreogeneous
activation of cell cycle checkpoints would likely result in stochastic
bypass of these checkpoints leading to inappropriate initiation of
DNA synthesis and/or precocious entry into mitosis, similar to the
stochastic activation of signaling networks that can promote
heterogeneity in tumor cells and stem cells.55–57 Such hetero-
geneity in cell cycle checkpoint activation may affect chemotherapy
response, induce a hyper-mutagenic tumor microenvironment,
and/or possibly contribute to cancer stem cell maintenance.
This is the first report to identify intrinsic subtype-associated cell
cycle checkpoint deregulation in breast cancer cell lines and a
potentially clinically relevant role for the decatenation G2
checkpoint. In addition, this work has provided a summary of S/
G2/M progression kinetics, genomic instability mechanisms, and
G2/M checkpoint defects associated with breast cancer subtypes
in a large cell line panel; these characteristics are often difficult to
predict by gene expression data alone due to the highly dynamic
nature of checkpoints, which often rely on kinase/phosphatase
activity and protein degradation pathways to initiate/sustain
checkpoint activation. In summary, the subtype-associated geno-
mic instability phenotypes described in this work may be useful
for the development of new targeted therapies for the LumB, BL,
and CL subtypes, may help identify biomarkers to serve as
predictive indicators of therapeutic response, and may explain the




At least four cell lines representing each of the intrinsic molecular subtypes
were assayed. Growth medium, conditions, and cell line source are detailed
in Table S7. Periodic tests for mycoplasma contamination using a
commercial kit were negative. PAM50 subtype calls were based on
microarray gene expression data.34
Cell proliferation markers
Cells were plated (day 0), fed (day 2), and treated (day 3) with 10 µM EdU
for 2 h and fixed. Samples were stained with: MPM2-Cy5, Click-It EdU-Alexa
488 substrate, and DAPI (See Table S9 for catalog numbers). All samples
were analyzed using a Beckman Coulter Dako CyAn ADP Analyzer at the
UNC Flow Cytometry Core Facility. At least 30,000 cells were analyzed per
sample and percentages of mitotic cells (MPM2+/4 N DNA content) or EdU+
cells (S phase) were quantified. Results were obtained from at least three
independent experiments for each cell line.
Population doubling level (PDL)
Cells were passaged approximately once a week and fed every 2–3 days
with fresh medium. The total number of cells recovered was determined
using a Beckman Coulter Counter Z1 instrument and PDL was calculated as
follows: PDL = [log(total number of cells recovered/total number of cells
plated)]/log2. PDL/week was calculated by determining the number of
PDLs occurring over an average 7 day period.
Flow cytometry MER assay
On day 3, cells were treated with 100 ng/mL colcemid and 0.1% DMSO, 4
µM ICRF-193, or 4 µM etoposide for 0, 2, 4, and 6 h. MPM2-Cy5/DAPI
staining of mitotic cells was performed. The rate of change in the percent
of cells in mitosis was calculated by regression of the linear portion of the
resulting line (2–6 h time points) and the slope of that line was used to
quantify MER (% of cells entering mitosis/h) as previously described.36
Results were obtained from at least three independent experiments for
each cell line.
Western immunoblotting
Standard immunoblotting techniques were used to detect phosphorylated
and total proteins as previously described.1 Total and phosphorylated
proteins were semi-quantified using Image J software v. 1.45 (NIH)
(Table S9—antibody list). Pixel intensities of each phosphorylated protein
were normalized to α-tubulin. The increment of increase in protein levels
for the drug-treated samples compared to DMSO samples were used to
measure protein activation. Values were subsequently normalized to the
increment measured for the same NHF1-hTERT positive control sample as




In vitro cell line genomic instability patterns
LumB •Defective decatenation G2 checkpoint
•Functional DNA damage G2 checkpoint
•Attenuated p-Ser15 p53 activation in response
to catalytic topo II inhibitor
•Low PDL
•Delayed progression of S or G2 phase
•Aneuploidy
•Functional SAC
BL •High MI, but low MER
•Aberrant regulation of S/G2/M progression




•Delayed progression of S and/or G2 phase
•Aneuploidy•Increased percentages of cohesion
defects
•Functional SAC
Her2E •Attenuated p-Ser15 p53 activation in response
to catalytic topo II inhibitor
•Low proliferation levels (S, MER, PDL)
•Aberrant regulation of S/G2/M progression
•Aneuploidy
Note: A summary of growth characteristics, G2/M checkpoint function, and
genomic instability patterns associated with each intrinsic subtype of
breast cancer cell lines
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an internal normalization control to facilitate comparisons among different
western blots and account for different exposures. Western blots shown
are representative of two independent experiments.
Spindle assembly checkpoint assay
Cells were incubated with 100 ng/mL colcemid or 0.1% DMSO (vehicle
control) for 0 or 24 h and then fixed, stained, and quantified as described
for the MER assay. Results were obtained from at least three independent
experiments for each cell line.
Cytogenetic studies
Metaphases were prepared as previously described,1 and examined using
an Olympus BH2 microscope (100X objective) with a SPOT RT camera. At
least 100 metaphases were scored for each treatment group/cell line when
available—if fewer than 100 metaphase cells were present, all metaphases
present were analyzed. All analyses were performed blinded to sample
identity.
Fluorescence in situ hybridization (FISH)
FISH samples were prepared as previously described.1 At least 100
metaphases were scored per cell line when available—if fewer than 100
metaphase cells were present, all metaphases present were analyzed. All
analyses were performed blinded to sample identity on a Zeiss LSM 700
Confocal Laser Scanning Microscope (UNC-CH Microscopy Services
Laboratory). The severity of cohesion defects was assessed based on a
previous study.42 Metaphases containing more than one type of cohesion
defect were categorized as exhibiting the most severe cohesion defect.
QTA and clinical outcomes analysis
Cell line gene expression data were obtained from Dr. Katherine Hoadley
and Dr. Charles M. Perou at the University of North Carolina—Chapel Hill
and is publicly available.34 Array data were Lowess normalized and
expressed as log2 ratios. Of the 24 cell lines comprising the panel, 22 were
present in the microarray dataset (R-HMEC-E and BT20 were unavailable).
QTA was performed using the significance analysis of microarrays (SAM)
package in R.58 Genes that significantly correlated with a quantitative trait
(such as % Inhibition of MER in the presence of ICRF-193 to represent
decatenation G2 checkpoint function) were selected to generate the gene
signature using the QTA tool provided within the SAM package at a low
FDR (≤0.1).59 These gene lists were subsequently applied to an
independent set of publically available clinical data containing overall
survival data, clinical annotations, PAM50 subtyping assignments, and
gene expression data for approximately 2000 breast cancer patients.45
Clinical outcome association analyses were performed using a Cox
proportional hazards model in the R survival package.
Statistical analyses
A set of LMMs were developed to compare the intrinsic subtype classes
with the HMEC class. All of the results presented in this manuscript are
supported by sensitivity analyses performed using the same data set after
removal of one or more highly influential data points (based on the well-
known Cook’s distance metric). If the statistical conclusions were the same
in both the primary and sensitivity analyses, it was concluded that the
particular observation did not unduly influence the analysis and the
primary analysis result was reported as statistically significant. All p-values,
95% confidence intervals, and details regarding the specific statistical
models employed for each individual analysis are included in the
supplementary information (SI). *p-value < 0.05, **p-value that remains
significant when controlling for false discovery rate (5%).
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